Efficacy and safety of treatments in Familial Mediterranean fever: a systematic review
Authors:
- 19 December 2015
- journal article
- review article
- Published by Springer Nature in Rheumatology International
- Vol. 36 (3) , 325-331
Abstract
Familial Mediterranean fever (FMF) is an autoinflammatory disease, which can be well controlled with lifelong use of colchicine. Since studies dealing with the efficacy and safety of colchicine were conducted mainly in the sixties and seventies of the previous century, it seems that this topic needs to be updated. Recently, an international expert panel was undertaken for the establishment of recommendations on how to manage FMF. We aimed to summarize the efficacy and safety of the current treatments available to prevent FMF attacks and to avert the appearance of amyloidosis secondary to FMF. A systematic review was performed. Two reviewers and methodologist established the protocol of the review and the epidemiological questions in PICO terms. MEDLINE through PubMed, Embase, and Cochrane Central Trials Register all up to May 31, 2014, were searched, and only randomized controlled trials or quasicontrolled trials were accepted. For each study, a judgment on risk of bias was then rated as high, moderate, or low. Of 1222 initially captured publications, 153 articles were studied in detail. Finally, only seven studies met all criteria and were included. Among these seven studies, four were randomized crossover clinical trials of colchicine including a total of 57 patients, one RCT of Andrographis paniculata Herba Nees extract employed in 24 patients, one randomized crossover clinical trial of Rilonacept used in 12 patients, and one RCT of interferon treating 34 acute abdominal attacks in 22 patients. The quality of the colchicine trials was low compared with the other drugs trials. Safety was not clearly mentioned in the trials. Colchicine is an effective treatment in FMF.Keywords
Funding Information
- EULAR
This publication has 23 references indexed in Scilit:
- Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectivesBest Practice & Research Clinical Rheumatology, 2012
- Severity scoring system for paediatric FMFNature Reviews Rheumatology, 2012
- Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1Clinical and Experimental Immunology, 2012
- A Glance at History and Future Perspectives of Childhood Autoinflammatory DisordersAnnals of Paediatric Rheumatology, 2012
- Evaluation of the current disease severity scores in paediatric FMF: is it necessary to develop a new one?Rheumatology, 2011
- Decrease in the rate of secondary amyloidosis in Turkish children with FMF: are we doing better?European Journal of Pediatrics, 2010
- Pregnancy outcomes in women with Familial Mediterranean Fever receiving colchicine: Is amniocentesis justified?Arthritis Care & Research, 2010
- Utilization of the PICO framework to improve searching PubMed for clinical questionsBMC Medical Informatics and Decision Making, 2007
- Double-blind, placebo-controlled, randomized, pilot clinical trial of ImmunoGuard® – a standardized fixed combination of Andrographis paniculata Nees, with Eleutherococcus senticosus Maxim, Schizandra chinensis Bail. and Glycyrrhiza glabra L. extracts in patients with Familial Mediterranean FeverPhytomedicine, 2003
- Colchicine in the Prevention and Treatment of the Amyloidosis of Familial Mediterranean FeverNew England Journal of Medicine, 1986